CFO Robert Hoffman to Leave Arena Pharmaceuticals
Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the resignation of Robert Hoffman, vice president, finance and chief financial officer (CFO). Hoffman, who has accepted a new position in the healthcare industry, will remain in his current role at Arena until the reporting of the company’s year-end results and the filing of the Form 10-K for the year ended 31 December 2010.
In the interim, Jennifer Bielasz, senior director of accounting and controller, and Carolyn Felzer, senior director of finance, will continue to play key roles in Arena’s finance department. Bielasz joined Arena in 2001 and is responsible for managing all accounting, stock administration and tax compliance activities. Previously, she served as the controller of both public and private companies, including as vice president and controller of Guild Mortgage Company.
Felzer joined Arena in 2006 and is responsible for public reporting, Sarbanes-Oxley (SOX) compliance, 401(k) and other administrative functions. Prior to joining Arena, she served as senior director of finance and administration at Salmedix, until its acquisition by Cephalon, and as corporate secretary and vice president and controller at Corvas International, until its acquisition by Dendreon.
Bielasz and Felzer both began their careers at KPMG.